|
Narcolepsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thirty-four of the 54 children were HLA-typed, and they were all positive for narcolepsy risk allele DQB1*0602/DRB1*15.
|
22470463 |
2012 |
|
Narcolepsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results illustrate the extraordinary conservation of HLA class II effects in narcolepsy across populations and show that DRB1*15:01 has no effect on narcolepsy susceptibility in the absence of DQB1*06:02.
|
22862152 |
2012 |
|
Narcolepsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To further define the genetic basis of narcolepsy risk, we performed a genome-wide association study (GWAS) in 562 European individuals with narcolepsy (cases) and 702 ethnically matched controls, with independent replication in 370 cases and 495 controls, all heterozygous for DRB1*1501-DQB1*0602.
|
20711174 |
2010 |
|
Narcolepsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The susceptibility alleles found in Mexicans with narcolepsy are also present in Japanese and Caucasians; DRB1*04 linked protection has also been shown in Koreans.
|
18706091 |
2008 |
|
Narcolepsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Complementary approaches were used to investigate residual predisposing effects of microsatellite alleles comprising the extended DRB1*15 haplotype taking into account the strong predisposing effect of DRB1*15: (1) Disease association of the extended DRB1*15 haplotype was compared for MS and narcolepsy families--predisposing effects were observed for extended class I microsatellite marker alleles in MS families, but not narcolepsy families; (2) disease association of the extended DRB1*15 haplotype was investigated after conditioning MS and control haplotypes on the absence of DRB1*15--a significant predisposing effect was observed for a 627-kb haplotype (D6S258 allele 8-MOGCA allele 4; MOG, myelin oligodendrocyte glycoprotein) spanning the extended class I region.
|
17256150 |
2007 |
|
Narcolepsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Several DRB1 (*0101, *0405, *0901) and DQB1 alleles (*0303, *0401, *0501, *0601, *0604) were found to have weak protective effects against narcolepsy.
|
17002906 |
2006 |
|
Narcolepsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The T-allele of the C-857T polymorphism was strongly associated with narcolepsy in the subgroup of DRB1*15/16 (HLA-DR2 type) negative patients, but not in DRB1*15/16 positive patients.
|
12823767 |
2003 |
|
Narcolepsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In previous studies, we suggested that the tumor necrosis factor (TNF-alpha and its receptor 2 (TNFR2) genes could be associated with the susceptibility to human narcolepsy, and that haplotype carrying DRB1*1502 had a negative association with the disorder.
|
11285131 |
2001 |
|
Narcolepsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although narcolepsy is highly associated with human leukocyte antigen (HLA) DQ6/DQB1*0602 and/or DR2/DRB1*1501, most individuals with the HLA haplotype are free of narcolepsy.
|
10777671 |
2000 |
|
Narcolepsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A genetic factor strongly associated with the disorder has been found in the human leukocyte antigen (HLA) class II region: the haplotype, DRB1*1501-DQB1*0602, predisposes to narcolepsy.
|
10488740 |
1999 |
|
Narcolepsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
DQB1*0602 was found to be a more sensitive marker for narcolepsy than DRB1*15 across all ethnic groups.
|
9456467 |
1997 |
|
Narcolepsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The haplotype DRB1*1501-DRB5*0101-DQA1*0102-DQB1*0602 was found to be significantly associated with the disease, while the haplotype DRB1*0701-DRB4*01-DQA1*0201-DQB1*02 might confer a slight protective effect against narcolepsy.
|
9534039 |
1997 |
|
Narcolepsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
In Black Americans, however, DRB1*1501 (DR2) was a poor marker for narcolepsy.
|
7701202 |
1994 |